NEW YORK, Sept. 17, 2018 /PRNewswire/ — INTRODUCTIONChronic affliction refers to the psychophysiological acknowledgment to an basal ytic condition, which is empiric to abide for a continuance greater than six months and is about above to assorted assay regimens. It is estimated that added than 1.5 billion individuals beyond the apple ache from this blazon of pain. Some of the best accepted physiological altitude that are characterized by a abiding awareness of affliction accommodate migraine, lower aback pain, affliction associated with cancer, arthritis-related affliction and neurogenic pain. Owing to the accelerated access of their alleviative effect, which offers absolute abatement with aerial efficacy, opioids are still advised to be one of the best broadly acclimated pharmacological interventions for the administering of abstinent to astringent forms of pain. However, these drugs are accepted to abet a beatific accompaniment aloft intake, about causing patients to corruption them; added recreational use of opioids has additionally been apparent to advance to biologic addiction. The over-prescription of such alleviative products, which promotes their misuse, is advised as one of the abject causes of the opioid crisis. In a contempo article, appear in 2017, 11.5 actor individuals were appear to accept been bent misusing decree opioids, while over 42,000 died from opioid overdose, in the US alone. Moreover, opioid corruption was estimated to accept been amenable for over USD 500 billion account of bread-and-er arrears (in the US) due to accident of abundance and healthcare costs.
Read the abounding report: https://www.reportlinker.com/p05563048
The opioid crisis has prompted biologic manufacturers to advance non-addictive, non-narcotic-based assay / gesics for the administering of pain. Unlike opioids, non-opioid drugs do not affect receptors present in the academician and, thus, are not addictive. These drugs assignment anon on afflicted / afflicted anatomy tissues and about block the assembly of prostaglandins by inhibiting the cyclooxygenase (COX) agitator at the armpit of abrasion / infection, thereby, abbreviating the bearing of affliction mediators aural the borderline afraid system. Additionally, there are assorted affliction administering accessories that accept been appear to decidedly abate or annihilate the charge for pharmacological interventions. Such accessories are added actuality acclimated to amusement a array of ytic altitude that are characterized by abiding affliction and activity the accessibility of actuality acclimated in the homecare ambience as well. However, it is acute for patients to argue able healthcare professionals, who accept the appropriate compassionate of such ameliorative options, above-mentioned to appliance such devices.
SCOPE OF THE REPORTThe “Non-Opioid Drugs for Abiding Affliction and Affliction Administering Accessories Market, 2018-2025” address provides an all-encompassing abstraction on the marketed, ytic and preclinical articles / artefact candidates for administering of abiding pain. The address additionally appearance a abundant overview of the accessories that are acclimated for the assay / administering of affliction associated with abiding ytic conditions. Amidst added elements, the address includes:• A abundant appraisal of the accepted bazaar mural of drugs actuality developed for the assay of abiding pain, accouterment advice on their corresponding developer(s), appearance of development (clinical, and preclinical / discovery), blazon of atom (small atom and biologic), adumbration (nociceptive and neuropathic), apparatus of activity (channel blockers, receptor antagonists, protein alleyway modulators and others) and avenue of administering (intra-articular, intravenous, intranasal, intranasal, intrathecal, oral, subcutaneous, contemporary and transdermal).• An all-embracing assay of the artefact activity and developer companies, featuring [A] a mirror assay highlighting the about acceptance of altered ache break based on the cardinal of molecules accessible / beneath development for anniversary adumbration and the cardinal of companies involved, [B] a logo mural of the assorted industry players complex in this domain, broadcast on the abject of breadth of address and aggregation admeasurement (small-sized, mid-sized and large), [C] a heptagon representation highlighting the administering of marketed and activity molecules based on their corresponding mechanisms of action, and [D] a carry assay highlighting the administering of molecules on the abject of date of development, avenue of administering and assay type.• An assay highlighting the key unmet needs beyond abiding pain, featuring insights generated from abstracts sourced from accommodating blogs, contempo accurate publications, amusing media posts and the angle of key appraisal leaders bidding on assorted online platforms.• An busy altercation on lifecycle administering strategies, anecdotic how altered companies are appliance assorted methods to prolong apparent age and, thereby, aggrandize business exclusivity in adjustment to accomplishment the acquirement bearing abeyant of their proprietary products. The breadth additionally includes abundant case studies elaborating on assorted lifecycle administering strategies of marketed drugs that are advancing apparent expiry.• Absolute profiles of drugs that are in appearance III of ytic development, with advice on developer companies (including breadth of address and year of establishment), blazon of molecule, apparatus of action, accepted cachet of development, avenue of administration, advice on ytic trials and key developments (if available).• A abundant appraisal of the accepted bazaar mural of assorted accessories that are actuality developed for abiding affliction management, highlighting advice on developer (size of aggregation and breadth of headquarters), apparatus of activity (electrical stimulation, electromagnetic pulse, calefaction therapy, ablaze therapy, radiofrequency dispatch and others), armpit of appliance on the anatomy (head, arm, knees and added areas), modality of the accessory (invasive and non-invasive), and assay requirements (at home and at hospitals / outpatient clinics), and blazon of accessory (wearable, hand-held and implants).• An astute 2X2 aggressive assay for the assorted devices, highlighting the best important articles based on the modality of device, assay requirement, blazon of device, and supplier ability (based on admeasurement of agent abject of the company). The affiliate additionally includes profiles of accessories that emerged as almost above (based on the ysis); anniversary contour appearance capacity on the developer (location of address and year of establishment), approval year, apparatus of action, key appearance and key developments.• An assay of the partnerships that accept been accustomed in the contempo past, accoutrement R&D collaborations, licensing agreements (related to both technology platforms and artefact candidates), artefact development and commercialization agreements, accomplishment agreements and others• An assay of investments fabricated at assorted stages of artefact development; these accommodate berry financing, adventure basic financing, debt costs and grants / awards, accustomed by companies that are operating in this domain.
One of the key objectives of the address was to accept the primary advance drivers and appraisal the approaching admeasurement of the market. Based on parameters, such as ambition customer segments, acceptable acceptance ante and accepted pricing, we accept provided an a appraisal of the acceptable change of the bazaar in the abbreviate to mid-term, for the aeon 2018-2025. The address includes a abundant bazaar assay on the abject of adumbration (chronic aback pain, lumbar radiculopathy, migraine, osteoarthritis and neuropathic pain), blazon of atom (small atom and biologic), apparatus of activity (CGRP inhibitors, COX/ NGF inhibitors, TRPV1 receptor antagonists, approach blockers and others) and cartography (North America, Europe, Asia Pacific and blow of the World). In addition, the address appearance an befalling assay for the abiding affliction administering accessories market. The opinions and insights presented in this abstraction were afflicted by inputs solicited via a absolute assay and discussions conducted with several key players in this domain. The address appearance abundant transcripts of interviews captivated with Ryan Jeffcoat (Director of Analytic Affairs & New Markets, AVACEN Medical), Lisa Robin (Chief Advocacy Officer, Federation of Accompaniment Medical Boards), Nelson Hendler (Chief Controlling Officer, Mensana Clinic Diagnostics) and Mark Wiederhold (Chief Controlling Officer, Virtual Reality Medical Center). All absolute abstracts accept been sourced and yzed from about accessible advice forums and inputs from primary research. Banking abstracts mentioned in this address are in USD, unless contrarily specified.
RESEARCH METHODOLOGYThe abstracts presented in this address has been aggregate via accessory and primary research. For all our projects, we conduct interviews with experts in the breadth (academia, industry, medical convenance and added associations) to accost their opinions on arising trends in the market. This is primarily advantageous for us to draw out our own appraisal on how the bazaar will advance beyond altered regions and technology segments. Where possible, the accessible abstracts has been arrested for accurateness from assorted sources of information.The accessory sources of advice include• Annual reports• Investor presentations• SEC filings• Industry databases• News releases from aggregation websites• Government activity documents• Industry ysts’ viewsWhile the focus has been on forecasting the bazaar till 2025, the address additionally provides our absolute appearance on assorted trends arising in the industry. This appraisal is alone based on our knowledge, assay and compassionate of the accordant bazaar aggregate from assorted accessory and primary sources of information.
CHAPTER OUTLINESChapter 2 provides an controlling arbitrary of the insights captured in our research. It offers a high-level appearance on the acceptable change of the non-opioid drugs and affliction administering accessories market, in the mid-long term.
Chapter 3 provides an accession to abiding affliction and associated ache indications. It appearance a abundant altercation on the allocation of pain, and affiliated affection and causes. The breadth additionally highlights the accessible ameliorative options for the assay / administering of this ytic condition. In addition, it summarizes the affidavit for the opioid crisis, and the accomplish actuality taken aural healthcare breadth to advance and acquaint alternative, non-opioid-based ameliorative strategies.
Chapter 4 highlights the key unmet needs associated with the administering and assay of abiding pain. The affiliate provides a abundant assay of such needs as articular from angle bidding by patients / industry experts beyond altered platforms, such as accommodating blogs, contempo accurate publications, amusing media posts and as discussed by key appraisal leaders at assorted conferences / symposiums. The affiliate additionally presents an astute affect assay and chat billow yses, summarizing the assorted opinions bidding beyond the above accessible portals.
Chapter 5 includes advice on over 160 non-opioid molecules that are currently accustomed / beneath development for ameliorative use. It appearance a absolute assay of marketed and activity molecules, highlighting the appearance of development (clinical and preclinical / assay stage) of artefact candidates, blazon of atom (small atom and biologic), sub-indication (nociceptive and neuropathic) apparatus of action, avenue of administering and advice on the developer companies (including breadth of address and year of establishment). In addition, it presents a set of key insights acquired from a mirror ysis, highlighting the about acceptance of the altered break based on the cardinal of molecules accessible / beneath development for anniversary adumbration and the cardinal of companies involved. The affiliate additionally appearance a heptagon representation highlighting the administering of the marketed and activity molecules based on altered mechanisms of activity and a logo mural of the assorted industry players complex in this market, broadcast on the abject of breadth of address and aggregation admeasurement (small-sized, mid-sized and large). Additionally, the affiliate appearance a carry assay highlighting the administering of molecules on the abject of date of development, avenue of administering and assay type.
Chapter 6 includes a abundant altercation on artefact activity aeon administering strategies that are actuality advised by developers of already accustomed / marketed drugs. It focuses on specific strategies, which are acclimated by biologic developers in this domain, to aggrandize apparent aegis and absorb the acquirement bearing abeyant of their proprietary articles after accepting to argue with the antagonism that is acceptable to be generated by all-encompassing versions.
Chapter 7 contains abundant profiles of drugs that are in appearance III of ytic development. Anniversary contour appearance an overview of the developer, advice on the avenue of administration, blazon of molecule, apparatus of action, accepted cachet of development, key ytic trials and key contempo developments (wherever available).
Chapter 8 includes advice on aing to 120 accessories that are currently accustomed / beneath assay for the assay / administering of abiding pain. It additionally appearance a absolute assay of the advice on developer (size of aggregation and breadth of headquarters), apparatus of action, armpit of appliance on the anatomy (head, arm, knees and added areas), modality of the accessory (invasive and non-invasive), assay claim (at home and at hospitals / outpatient clinics), blazon of accessory (wearable, hand-held and implants) and apparatus of activity of accessory (electrical stimulation, radiofrequency stimulation, calefaction assay and others) .
Chapter 9 provides a absolute 2X2 assay featuring a allusive overview of all the accessible / beneath development accessories for abiding affliction management. The assay compares the articles based on the modality of device, assay requirement, blazon of device, supplier ability (based on admeasurement of agent abject of the company). Further, the affiliate appearance abundant profiles of accessories which appeared to be almost above to added articles / artefact candidates. Anniversary of these profiles accommodate capacity on their developer (location of address and year of establishment), approval year of the product, apparatus of action, key appearance and key developments.
Chapter 10 appearance an assay of the assorted collaborations and partnerships that accept been active amidst players in this market. We accept additionally discussed the altered affiliation models (including artefact development and commercialization, R&D agreements, technology / artefact licensing agreements, added licensing agreements, mergers / acquisitions and ytic balloon collaborations) and the best accepted forms of deals / agreements that accept been accustomed amid 2012 to 2018.
Chapter 11 presents capacity on assorted investments accustomed by baby sized companies that are affianced in this domain. It additionally includes a abundant assay of the allotment instances that accept taken abode amid January 2001 and April 2018, highlighting the growing absorption of the adventure basic association and added cardinal investors in this domain.
Chapter 12 presents a absolute bazaar anticipation ysis, highlighting the approaching abeyant of non-opioid drugs in abiding affliction market, till the year 2025. We accept absolute the befalling on the abject of adumbration (chronic aback pain, lumbar radiculopathy, migraine, osteoarthritis and neuropathic pain), blazon of atom (small atom and biologic), apparatus of activity (CGRP inhibitors, COX/ NGF inhibitors, TRPV1 receptor antagonists, approach blockers and others) and cartography (North America, Europe, Asia Pacific and blow of the World). Approaching sales abeyant and advance befalling were estimated based on acceptable acceptance ante and the advancing amount of products. The address appearance an befalling assay for abiding affliction administering accessories as well.
Chapter 13 summarizes the all-embracing report. In this chapter, we accept provided a account of key takeaways from the report, and bidding our absolute appraisal accompanying to the assay and assay declared in the antecedent chapters.
Chapter 14 is a accumulating of account transcripts of the discussions captivated with key stakeholders in this market. In this chapter, we accept presented the capacity of our conversations with (in alphabetical adjustment of aggregation name) Ryan Jeffcoat (Director of Analytic Affairs & New Markets, AVACEN Medical), Lisa Robin (Chief Advocacy Officer, Federation of Accompaniment Medical Boards), Nelson Hendler (Chief Controlling Officer, Mensana Clinic Diagnostics), and Mark Wiederhold (Chief Controlling Officer, Virtual Reality Medical Center).
Chapter 15 is an appendix, which provides archival abstracts and numbers for all the abstracts included in the report.
Chapter 16 is an appendix, which contains the account of companies and organizations mentioned in the report.
EXAMPLE HIGHLIGHTS1. An assay of agreeable presented on breezy (over 200 accommodating blogs and over 10,000 amusing media posts) and academic (over 200 accurate abstract studies) arcane sources, and the opinions accurate by industry experts, affirm the actuality of a cogent unmet charge aural the abiding affliction administering market. Some of the unaddressed apropos accent on assorted portals accommodate abnormal diagnosis, poor affection of life, and dearth of non-addictive therapies to administer abiding pain.2. Presently, over 145 non-opioid artefact candidates are marketed / beneath appraisal beyond assorted stages of development for the administering of abiding affliction acquired due to assorted ytic conditions. There are eight commercialized products; of these, three drugs accustomed approval column 2017, namely Zilretta® (2017), ZTlido™ (2018) and Aimovig™ (2018). Amidst the drugs that are in ytic development, 15% are in appearance III, 30% in appearance II, and 19% in appearance I. Nearly 30% of the molecules are in preclinical or assay phase.3. It is account acquainted that 31% candidates abet affliction abatement by inhibiting the activity of receptors such as TRPV 1 and serotonin, 20% molecules act as approach blockers (primarily calcium, potassium and sodium approach blockers), while 18% of artefact candidates are protein inhibitors (which accommodate COX-2 and NGF). 31% of the activity includes anti-inflammatory, anti-CGRP and alleyway modulating molecules.4. Majority of the drugs (54%) are actuality developed for administering of neuropathic affliction (which includes break such as diabetic neuropathic pain, post-herpetic neuralgia, fibromyalgia, cancer-related neuropathic pain, and HIV-related neuropathic pain). It is account advertence that three out of the seven commercialized drugs are advised for assay of post-herpetic neuralgia. Nearly 35% of molecules are actuality developed for managing nociceptive pain, of which, majority of the candidates are meant for the assay of osteoarthritis and migraine. Blow (11%) of the drugs are actuality developed for managing abiding pain, for which specific break are not known.5. The bazaar mural is characterized by the attendance of ample (29%), mid-sized (18%) and small-sized companies (49%). Of the accustomed biologic companies, two players accept afresh accustomed approval for their non-opioid drugs for abiding affliction management; namely (in alphabetical order, no alternative criteria) Arbor Pharmaceuticals and Horizon Pharma. In addition, four mid-sized players, which accommodate (in alphabetical order) Acorda Therapeutics, DepoMed, Flexion Assay and Sorrento Assay accept additionally accustomed the FDA’s approval and marketed their non-opioid candidates beyond assorted geographies. The growing unmet charge for able non-opioid drugs for abiding affliction administering accept spurred the enactment of abounding start-ups in contempo years; examples accommodate (in alphabetical order, no alternative criteria) 4P Therapeutics, Acorda Therapeutics, Adyn, Anavex, Araim Pharmaceuticals, BioHealthonomics, DermaXon, Hydra Biosciences, Levicept, Mapi Pharma, Regulonix, Saniona, Solasia Pharma and Winsantor.6. In accession to pharmacological interventions, there are over 120 accessories accessible for abiding affliction management. Of these, 30% pf articles charge to be surgically placed central the body, these accommodate articles such as (in alphabetical order, no alternative criteria) Algovita®, Axium™ Neurostimulator System, Eon Mini™, Genesis, Halo CFNS System, Intellis™ System, Precision Spectra™, Proclaim™ DRG, RestoreAdvanced™ Surescan™ MRI, StimQ PNS System, SynchroMed™ II, VersaStim®, and Vivendi. Further, 25% of the articles that we came beyond were wearable devices, such as (in alphabetical order, no alternative criteria) Aleve Direct Assay (worn at the back), ElectroMesh Garments (worn at the armpit of pain), Neuro-stim Arrangement (applied in the ear) and Quell Abatement (wrapped about the leg). In addition, 17% of the accessories activity featured handheld accessories that can be activated at the breadth of affliction in the body, such as (in alphabetical order, no alternative criteria) BioBeam™ 940, Handy Beating Laser, Iovera, LaserTouchOne™, MyACT®, NexWave, Sanakey and Silk’n Relif. We additionally empiric that probes, such as such as (in alphabetical order, no alternative criteria) COOLIEF, Dolphin Neurostim™, Intracept® Intraosseous Nerve Ablation System, anon aggregate 7% of the absolute cardinal of accessory based ameliorative options in the pipeline. It is additionally account pointing out that a cogent cardinal of accessories (21%) could not be classified beneath any of the above categories, these accommodate articles such as (in alphabetical order, no alternative criteria) COOL! And GLOW!, NeuroCare (Digital) and Freedom (Analog), sTMS mini and The WellnessPro™ Plus.7. The affliction administering accessories mural is characterized by the attendance of ample (8), mid-sized (13) and baby sized (46) companies. Some of the noteworthy ample sized accessory developers accommodate (in alphabetical order, no alternative criteria) Bayer, Boston Scientific, Chattem, Medtronic and St Jude Medical. Of these, St Jude Medical was empiric to accept the best affliction administering accessories in its database. In addition, 13 mid-sized companies accept developed 18 affliction abatement devices; notable examples of these companies accommodate (in alphabetical order, no alternative criteria) Bioness, Flownix, Gradient Medical, Mainstay Medical, Neuvectra, PainPod and Zynex. Interestingly, several small-sized companies accept taken initiatives in developing the affliction administering devices; examples accommodate (in alphabetical order, no alternative criteria) AcuKnee, AVACEN Medical, BioElectronics. BlueWind Medical, cafaly Tecchnologies, DavaRay, ElectroCore, LightStim, Meagan Medical, Med-Ally, Prizm Medical, Renewal Technologies, Syrolight, TENS Rx, Vital Motion and Xavant Technology.8. Stakeholders in the industry accept artificial several cardinal partnerships in the contempo past; we empiric that over 26% of the agreements that accept been active amid 2012 and 2018 were accompanying to the commercialization of products. These were followed by acquisitions (23%), assay and development collaborations (12%), licensing agreements (12%), artefact development and commercialization agreements (11%), artefact development agreements (8%), ytic balloon collaborations (2%) and artefact administering agreements (2%). Examples of afresh active deals accommodate accord amid Alder BioPharmaceuticals and Teva Biologic (January 2018), Grünenthal and Mundipharma (January 2018), Saniona and Proximagen (January 2018).9. Biologic development initiatives by start-ups accept accustomed banking abutment in agreement of adventure allotment and assay grants. In fact, added than USD 1.5 billion beyond 81 instances of grants, adventure basic circuit and accessible offerings accept been invested in these companies back 2000. Alta Partners, ARCH Adventure Partners, Abingworth Management, Advanced Technology Ventures, Biovenutures Investors, Frazier Healthcare Partners, Lilly Ventures, Montreux Equity Partners and Walden International accept emerged as some of the arresting investors, in agreement of their accord in the best cardinal of allotment instances empiric in the accustomed time period.10. We apprehend the non-opioid drugs for abiding affliction administering bazaar to abound at an annualized amount of ~40% amid 2018 and 2025. North America (primarily US) abduction the better bazaar allotment (close to 80%), followed by Europe (France, Germany, Italy, Spain and the UK) Australia, South Korea and Japan. With three accustomed drugs, osteoarthritis currently captures the accomplished bazaar allotment amidst all the indications. By 2025, in accession to osteoarthritis, the bazaar is acceptable to be apprenticed by break such as cephalalgia and neuropathic pain.11. Artefact candidates, such as Aimovig™, fasinumab, fremanezumab, galcanezumab and tanezumab, which accept accustomed or are accepted to accept approval for the assay of cephalalgia by backward 2018 / aboriginal 2019 are best acceptable to accomplish blockbuster cachet in the future. With account to the biologic class, the accepted bazaar allotment is broadcast amid anti-CGRP drugs (41%) and histamine receptor antagonists (32%). By 2025, the bazaar allotment is acceptable to be broadcast amidst anti-CGRP drugs (54%), followed by NGF inhibitors (20%) and calcium / sodium approach blockers (16%).
Read the abounding report: https://www.reportlinker.com/p05563048
About ReportlinkerReportLinker is an award-winning bazaar assay solution. Reportlinker finds and organizes the latest industry abstracts so you get all the bazaar assay you charge – instantly, in one place.
__________________________ Contact Clare: [email protected]: (339)-368-6001 Intl: 1 339-368-6001
Appearance aboriginal content:https://www.prnewswire.com/news-releases/non-opioid-drugs-for-chronic-pain-and-pain-management-devices-market-2018-2025-300713754.html
Ten Things To Avoid In Psychotherapy Intake Form | Psychotherapy Intake Form – psychotherapy intake form
| Pleasant to be able to the website, on this moment I’ll teach you about psychotherapy intake form
. And after this, this can be the initial picture: